参考文献

1.Garran C，Ciervide R，Cambeiro M，et al.Relationship between day O dosimeters and biochemical relapse-free survival in patients treated with fransperineal permanent prostate interstitial brachytherapy with 125I seeds.Brachytherapy，2010，9：8-14.

2.Rivard MJ，Melhus CS，Sioshansi S，et al.The impact of prescription depth，dose rate，plaque size，and source loading on the central axis using 103Pd，125I，and 131Cs.Brachytherapy，2008，7：327-335.

3.Pignol J，Rakovitch E，Keller B，et al.Final tolerance and acceptance results of a phaseⅠ/Ⅱ clinical trial of permanent breast 103Pd seed implant.Brachytherapy，2008，7：111-121.

4.Adkison JB，Thomadsen B，Howard SP.Systemic iodine-125 activity after Glia Site brachytherapy：Safety considerations.Brachytherapy，2008，7：43-46.

5.Revard MJ，Bulter WM，Devlin WM，et al.American Brachytherapy Society recommends no change for prostate permanent implant dose prescriptions using iodine-125 or palladium-103.Brachytherapy，2007，6：34-37.

6.Potters L，Calugaru E，Jassal A，et al.Is there a role for postimplant dosimety after real-time dynamic permanent prostate brachytherapy? Int J Radiation Oncology Biol phys，2006，65：1014-1019.